Is gefapixant available in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Gefapixant Availability in India

Gefapixant is NOT currently available in India. The drug has received regulatory approval in several countries including Japan, Switzerland, and the European Union for treatment of refractory or unexplained chronic cough, but it has not been approved by India's Central Drugs Standard Control Organisation (CDSCO) as of current evidence.

Current Regulatory Status

Based on the available evidence, gefapixant's approval status is limited to specific markets:

  • Approved markets: The drug has gained approval in multiple countries for chronic cough treatment 1
  • India-specific status: No evidence in the provided literature indicates approval or availability in India
  • Access pathway: Indian patients would need to explore compassionate use programs or medical tourism to access gefapixant, as it is not commercially available domestically

Clinical Context for Indian Practitioners

If you are managing a patient with refractory chronic cough in India, gefapixant is not a treatment option you can prescribe locally. The evidence shows gefapixant is effective for chronic cough, with:

  • Efficacy: 28.1% reduction in 24-hour cough frequency at therapeutic doses (90.7 mg/day ED50) 2
  • Real-world response: 50% of patients report meaningful improvement (≥5/10 response rate), with 25% reporting excellent response (≥8/10) 3
  • Rapid onset: Improvement typically seen within 2 weeks in responders 3

However, the drug carries significant tolerability concerns:

  • Taste disturbances: 38% absolute risk increase for dysgeusia/hypogeusia, which is dose-dependent 2
  • Discontinuation: Higher rates due to taste-related adverse effects 2

Alternative Management in India

Since gefapixant is unavailable, focus on evidence-based alternatives for refractory chronic cough:

  • GERD-directed therapy: Intensive medical regimen including PPIs, prokinetic agents, and dietary modifications (≤45g fat/day, avoiding coffee, tea, alcohol, chocolate, citrus) 4
  • Treatment duration: Medical therapy for GERD-related cough improves symptoms in 70-100% when not limited to acid suppression alone 4
  • Surgical option: Anti-reflux surgery improves cough in approximately 85% of patients who fail intensive medical therapy 4

Monitor regulatory updates from CDSCO for potential future approval of gefapixant in India.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.